Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3

BACKGROUND: Despite striking successes, immunotherapies aimed at increasing cancer-specific T cell responses are unsuccessful in most patients with cancer. Inactivating regulatory T cells (Treg) by inhibiting the PI3Kδ signaling enzyme has shown promise in preclinical models of tumor immunity and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauder, Sarah Nicol, Smart, Kathryn, Kersemans, Veerle, Allen, Danny, Scott, Jake, Pires, Ana, Milutinovic, Stefan, Somerville, Michelle, Smart, Sean, Kinchesh, Paul, Lopez-Guadamillas, Elena, Hughes, Ellyn, Jones, Emma, Scurr, Martin, Godkin, Andrew, Friedman, Lori S, Vanhaesebroeck, Bart, Gallimore, Awen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583804/
https://www.ncbi.nlm.nih.gov/pubmed/33093155
http://dx.doi.org/10.1136/jitc-2020-000693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583804/
https://www.ncbi.nlm.nih.gov/pubmed/33093155
http://dx.doi.org/10.1136/jitc-2020-000693

Ejemplares similares